MAPK3 and COVID-19: Network pharmacology and molecular docking studies of XBF show that it has effect in the treatment of COVID-19 patients, by regulating key targets such as IL6, MAPK3, MAPK1, IL1β, CCL2, EGFR.[15] This study aims to evaluate the effectiveness and safety of XBF in the treatment of COVID-19, and to provide ways for the treatment of COVID-19.